Dr. Deborah Mash, Founder of DemeRx, discovered and advanced the science behind the molecules ibogaine and noribogaine. Dr. Mash spent over thirty years conducting both preclinical and clinical studies working with ibogaine in the first and only FDA approved clinical trial. She and her team identified noribogaine as a long-acting metabolite that may mediate some of the beneficial aftereffects of ibogaine detoxification.

Our review of clinical data from over 250 patients who used ibogaine for drug and alcohol detoxification supports the safety, efficacy, and the non-hallucinogenic effects of noribogaine.

DemeRx has secured GMP drug supplies of noribogaine and the company stands ready to work with government and industry partners to address the worldwide alcohol abuse problem.

Noribogaine is derived from ibogaine, a naturally occurring compound originally developed and studied in France, where it was marketed in low dose formulations from 1939 – 1970. We demonstrated in our early US FDA clinical trials conducted at the University of Miami that low doses of ibogaine are totally converted by the liver to noribogaine. 

Noribogaine promotes neuroplasticity to improve mood and prevent the cravings that occur in early recovery that drives relapse. It is free from the hallucinogenic effects of ibogaine and is safe enough for daily use.